Ignite Creation Date:
2024-05-06 @ 2:34 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02074449
Status:
COMPLETED
Last Update Posted:
2016-11-17
First Post:
2014-02-26
Brief Title:
Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil Remodulin
Sponsor:
University of Arizona
Organization:
University of Arizona
Study Overview
Official Title:
Comprehensive Characterization Of Right Ventricular Performance And Afterload In Patients With Pulmonary Arterial Hypertension Undergoing Initiation And Rapid Dose Escalation Of Treprostinil
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ISS
Brief Summary:
Patients with pulmonary arterial hypertension PAH are at much higher risk of death if the RV right ventricle is weak The purpose of this study is to get a better understanding of the factors that determine RV adaptation and how the RV compensates on therapy The investigator is also interested in how Remodulin treprostinil infused over a short period approximately 48-72 hours affects the patients quality of life medical care and personal health behaviors
Treprostinil also known as Remodulin has been approved by the US Food and Drug Administration for use in the treatment of PAH The investigator has been treating patients with Remodulin by rapid infusion over 48 hours for over 6 years The investigator would like to establish this practice as safe and effective for the benefit of other centers that treat PAH
Treprostinil also known as Remodulin has been approved by the US Food and Drug Administration for use in the treatment of PAH The investigator has been treating patients with Remodulin by rapid infusion over 48 hours for over 6 years The investigator would like to establish this practice as safe and effective for the benefit of other centers that treat PAH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None